WHO, Depressive disorder. (depression). https://www.who.int/news-room/fact-sheets/detail/depression.

Otte C, Gold SM, Penninx BW, Pariante CM, Etkin A, Fava M, et al. Major depressive disorder. Nat Rev Dis Primers. 2016;2:16065. https://doi.org/10.1038/nrdp.2016.65.

Article  PubMed  Google Scholar 

Fasipe OJ. Neuropharmacological classification of antidepressant agents based on their mechanisms of action. Archives Med Health Sci. 2018;6(1):81–94. https://doi.org/10.4103/amhs.amhs_7_18.

Article  Google Scholar 

Gartlehner G, Thieda P, Hansen RA, Gaynes BN, Deveaugh-Geiss A, Krebs EE. Comparative risk for harms of second-generation antidepressants: a systematic review and meta-aNElysis. Drug Saf. 2008;31:851–65. https://doi.org/10.2165/00002018-200831100-00004.

Article  CAS  PubMed  Google Scholar 

Shelton RC. Serotonin and norepinephrine reuptake inhibitors. Handb Exp Pharmacol. 2019;250:145–80. https://doi.org/10.1007/164_2018_164.

Article  CAS  PubMed  Google Scholar 

Label of SPRAVATO®. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211243s004lbl.pdf.

Dunlop BW, Nemeroff CB. The role of dopamine in the pathophysiology of depression. Arch Gen Psychiatry. 2007;64(3):327–37. https://doi.org/10.1001/archpsyc.64.3.327.

Article  CAS  PubMed  Google Scholar 

Guiard BP, Chenu F, El Mansari M, Blier P. Characterization of the electrophysiological properties of triple reuptake inhibitors on monoaminergic neurons. Int J Neuropsychopharmacol. 2011;14(2):211–23. https://doi.org/10.1017/S1461145710000076.

Article  CAS  PubMed  Google Scholar 

Trivedi MH, Fava M, Wisniewski SR, Thase ME, Quitkin F, Warden D, et al. STAR*D study team. Medication augmentation after the failure of SSRIs for depression. N Engl J Med. 2006;354(12):1243–52. https://doi.org/10.1056/NEJMoa052964.

Article  CAS  PubMed  Google Scholar 

Zisook S, Rush AJ, Haight BR, Clines DC, Rockett CB. Use of bupropion in combination with serotonin reuptake inhibitors. Biol Psychiatry. 2006;59(3):203–10. https://doi.org/10.1016/j.biopsych.2005.06.027.

Article  CAS  PubMed  Google Scholar 

Kamijima K, Kimura M, Kuwahara K, Kitayama Y, Tadori Y. Randomized, double-blind comparison of aripiprazole/sertraline combination and placebo/sertraline combination in patients with major depressive disorder. Psychiatry Clin Neurosci. 2018;72(8):591–601. https://doi.org/10.1111/pcn.12663.

Article  CAS  PubMed  Google Scholar 

Chen Z, Skolnick P. Triple uptake inhibitors: therapeutic potential in depression and beyond. Expert Opin Investig Drugs. 2007;16(9):1365–77. https://doi.org/10.1517/13543784.16.9.1365.

Article  PubMed  Google Scholar 

Sharma H, Santra S, Dutta A. Triple reuptake inhibitors as potential next-generation antidepressants: a new hope? Future Med Chem. 2015;7(17):2385–406. https://doi.org/10.4155/fmc.15.134.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vasiliu O, Efficacy. Tolerability, and Safety of Toludesvenlafaxine for the Treatment of Major Depressive Disorder-A Narrative Review. Pharmaceuticals (Basel). 2023;16(3):411. https://doi.org/10.3390/ph16030411. Published 2023 Mar 8.

Article  CAS  PubMed  Google Scholar 

Zhu H, Wang W, Sha C, Guo W, Li C, Zhao F, et al. Pharmacological characterization of Toludesvenlafaxine as a triple reuptake inhibitor. Front Pharmacol. 2021;12:741794. https://doi.org/10.3389/fphar.2021.741794.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mi W, Di X, Wang Y, Li H, Xu X, Li L, et al. A phase 3, multicenter, double-blind, randomized, placebo-controlled clinical trial to verify the efficacy and safety of ansofaxine (LY03005) for major depressive disorder. Transl Psychiatry. 2023;13(1):163. https://doi.org/10.1038/s41398-023-02435-0.

Article  CAS  PubMed  PubMed Central  Google Scholar 

NMPA. https://www.nmpa.gov.cn/zhuanti/cxylqx/cxypxx/20221103083801194.html. (Chinese).

Murali D, Barnhart TE, Vandehey NT, Christian BT, Nickles RJ, Converse AK, et al. An efficient synthesis of dopamine transporter tracer [18F]FECNT. Appl Radiat Isot. 2013;72:128–32. https://doi.org/10.1016/j.apradiso.2012.10.010.

Article  CAS  PubMed  Google Scholar 

Goodman MM, Kilts CD, Keil R, Shi B, Martarello L, Xing D, et al. 18F-labeled FECNT: a selective radioligand for PET imaging of brain dopamine transporters. Nucl Med Biol. 2000;27(1):1–12. https://doi.org/10.1016/s0969-8051(99)00080-3.

Article  CAS  PubMed  Google Scholar 

Wong JM, Malec PA, Mabrouk OS, Ro J, Dus M, Kennedy RT. Benzoyl chloride derivatization with liquid chromatography-mass spectrometry for targeted metabolomics of neurochemicals in biological samples. J Chromatogr A. 2016;1446:78–90. https://doi.org/10.1016/j.chroma.2016.04.006.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wu L, Liu J, Feng X, Dong J, Qin W, Liu Y, et al. 11 C-CFT-PET in Presymptomatic FTDP-17: a potential Biomarker Predicting Onset. J Alzheimers Dis. 2018;61(2):613–8. https://doi.org/10.3233/JAD-170561.

Article  CAS  PubMed  Google Scholar 

Zhang YF, Wang XY, Cao L, Guo QY, Wang XM. Effects of hypoxic-ischemic brain injury on striatal dopamine transporter in newborn piglets: evaluation of 11 C-CFT PET/CT for DAT quantification. Nucl Med Biol. 2011;38(8):1205–12. https://doi.org/10.1016/j.nucmedbio.2011.05.001.

Article  CAS  PubMed  Google Scholar 

Shang Y, Gibbs MA, Marek GJ, Stiger T, Burstein AH, Marek K, et al. Displacement of serotonin and dopamine transporters by venlafaxine extended release capsule at steady state: a [123I]2beta-carbomethoxy-3beta-(4-iodophenyl)-tropane single photon emission computed tomography imaging study. J Clin Psychopharmacol. 2007;27(1):71–5. https://doi.org/10.1097/JCP.0b013e31802e0017.

Article  CAS  PubMed  Google Scholar 

Kugaya A, Seneca NM, Snyder PJ, Williams SA, Malison RT, Baldwin RM, et al. Changes in human in vivo serotonin and dopamine transporter availabilities during chronic antidepressant administration. Neuropsychopharmacology. 2003;28(2):413–20. https://doi.org/10.1038/sj.npp.1300036.

Article  CAS  PubMed  Google Scholar 

De Win MM, Habraken JB, Reneman L, van den Brink W, den Heeten GJ, Booij J. Validation of [(123)I]beta-CIT SPECT to assess serotonin transporters in vivo in humans: a double-blind, placebo-controlled, crossover study with the selective serotonin reuptake inhibitor citalopram. Neuropsychopharmacology. 2005;30(5):996–1005. https://doi.org/10.1038/sj.npp.1300683.

Article  CAS  PubMed  Google Scholar 

Meyer JH, Wilson AA, Sagrati S, Hussey D, Carella A, Potter WZ, et al. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11 C]DASB Positron emission tomography study. Am J Psychiatry. 2004;161(5):826–35. https://doi.org/10.1176/appi.ajp.161.5.826.

Article  PubMed  Google Scholar 

Zhou FC, Lesch KP, Murphy DL. Serotonin uptake into dopamine neurons via dopamine transporters: a compensatory alternative. Brain Res. 2002;942(1–2):109–19. https://doi.org/10.1016/s0006-8993(02)02709-9.

Article  CAS  PubMed  Google Scholar 

Meyer JH, Goulding VS, Wilson AA, Hussey D, Christensen BK, Houle S. Bupropion occupancy of the dopamine transporter is low during clinical treatment. Psychopharmacology. 2002;163(1):102–5. https://doi.org/10.1007/s00213-002-1166-3.

Article  CAS  PubMed  Google Scholar 

McCabe C, Cowen PJ, Harmer CJ. Neural representation of reward in recovered depressed patients. Psychopharmacology. 2009;205(4):667–77. https://doi.org/10.1007/s00213-009-1573-9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Treadway MT, Zald DH. Reconsidering anhedonia in depression: lessons from translational neuroscience. Neurosci Biobehav Rev. 2011;35(3):537–55. https://doi.org/10.1016/j.neubiorev.2010.06.006.

Article  PubMed  Google Scholar 

Der-Avakian A, Markou A. The neurobiology of anhedonia and other reward-related deficits. Trends Neurosci. 2012;35(1):68–77. https://doi.org/10.1016/j.tins.2011.11.005.

Article  CAS  PubMed  Google Scholar 

Schultz W. Predictive reward signal of dopamine neurons. J Neurophysiol. 1998;80(1):1–27. https://doi.org/10.1152/jn.1998.80.1.1.

Article  CAS  PubMed  Google Scholar 

Salamone JD, Correa M, Mingote S, Weber SM. Nucleus accumbens dopamine and the regulation of effort in food-seeking behavior: implications for studies of natural motivation, psychiatry, and drug abuse. J Pharmacol Exp Ther. 2003;305(1):1–8. https://doi.org/10.1124/jpet.102.035063.

Article  CAS  PubMed  Google Scholar 

Szczypiński JJ, Gola M. Dopamine dysregulation hypothesis: the common basis for motivational anhedonia in major depressive disorder and schizophrenia? Rev Neurosci. 2018;29(7):727–44. https://doi.org/10.1515/revneuro-2017-0091.

Article  CAS  PubMed  Google Scholar 

Forbes EE, Hariri AR, Martin SL, Silk JS, Moyles DL, Fisher PM, et al. Altered striatal activation predicting real-world positive affect in adolescent major depressive disorder. Am J Psychiatry. 2009;166(1):64–73. https://doi.org/10.1176/appi.ajp.2008.07081336.